CLAIMS

[Claim 1]

A combination pharmaceutical kit for treating cancer comprising REIC/Dkk-3 in combination with a check point inhibitor.

[Claim 2]

The combination pharmaceutical kit of claim 1, wherein the check point inhibitor is an anti-PD-1 antibody or anti-PD-L1 antibody.

[Claim 3]

The combination pharmaceutical kit of claim 1, wherein an adenovirus vector comprising REIC/Dkk-3 gene is comprised.

[Claim 4]

The combination pharmaceutical kit of claim 1, wherein the cancer is a prostate cancer.

[Claim 5]

Use of a composition in the manufacture of a medicament for treating cancer in a patient, wherein the composition is a REIC/Dkk-3 gene and a check point inhibitor.

[Claim 6]

The use of claim 5, wherein the check point inhibitor is an anti-PD-1 antibody or anti-PD-L1 antibody.

[Claim 7]

The use of claim 5, wherein an adenovirus vector comprising REIC/Dkk-3 gene is administered.

[Claim 8]

The use of claim 5, wherein the cancer is a prostate cancer.

[Claim 9]

Use of a composition in the manufacture of a medicament for treating cancer, wherein the composition combines a REIC/Dkk-3 with a check point inhibitor.

[Claim 10]

The use according to claim 9, wherein the check point inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.

[Claim 11]

The use according to claim 9, wherein the check point inhibitor is an anti-PD-1 antibody.

[Claim 12]

The use according to claim 9, wherein the check point inhibitor is an anti-PD-L1 antibody.

[Claim 13]

Use of anti-PD-1 and anti-PD-L1 antibodies in the manufacture of a medicament for manipulating the immune system such that cancer expresses PD-1 and PD-L1 on the cell surface making it susceptible to REIC/Dkk-3 gene (REIC/Dkk-3-induced anti-tumor immunity; CTLs induced by REIC/Dkk-3).